Dopamine D3 receptor knock-out mice display deficits in locomotor sensitization after chronic morphine administration

Neuroscience Letters

Volumn 485, Issue 3, 2010, Pages 256-260

  Li, Tao ^a,b   Hou, Ying ^c   Yan, Chun xia ^a,b   Chen, Teng ^a,b   Zhao, Yan ^a,b   Li, Sheng bing ^a,b  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

^b Ministry of Health for Forensic Sciences   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Dopamine D3 receptor knock out; Locomotor sensitization; Morphine; Nafadotride; Naloxone

Indexed keywords

DOPAMINE 3 RECEPTOR; MORPHINE; NAFADOTRIDE; NALOXONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; GENE DELETION; GENE SILENCING; HYPERACTIVITY; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR GENE; SENSITIZATION;

ANALGESICS, OPIOID; ANIMALS; DOPAMINE ANTAGONISTS; MALE; MICE; MICE, KNOCKOUT; MORPHINE; MOTOR ACTIVITY; NALOXONE; NAPHTHALENES; NARCOTIC ANTAGONISTS; PYRROLIDINES; RECEPTORS, DOPAMINE D3; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 77957888109     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.09.025     Document Type: Article

References (33)

1. Accili D., Fishburn C.S., Drago J., Steiner H., Lachowicz J.E., Park B.H., Gauda E.B., Lee E.J., Cool M.H., Sibley D.R., Gerfen C.R., Westphal H., Fuchs S. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:1945-1949.
2. Cami J., Farre M. Drug addiction. N. Engl. J. Med. 2003, 349:975-986.
3. Carlezon W.A., Nestler E.J. Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse?. Trends Neurosci. 2002, 25:610-615.
4. Cervo L., Carnovali F., Stark J.A., Mennini T. Cocaine-seeking behavior in response to drug-associated stimuli in rats: involvement of D3 and D2 dopamine receptors. Neuropsychopharmacology 2003, 28:1150-1159.
5. Chen P.C., Lao C.L., Chen J.C. Dual alteration of limbic dopamine D1 receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D3 receptor mutants during the development of methamphetamine sensitization. J. Neurochem. 2007, 100:225-241.
6. Chiang Y.C., Chen P.C., Chen J.C. D(3) dopamine receptors are down-regulated in amphetamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine. Brain Res. 2003, 972:159-167.
7. Cook C.D., Beardsley P.M. The modulatory actions of dopamine D2/3 agonists and antagonists on the locomotor-activating effects of morphine and caffeine in mice. Pharmacol. Biochem. Behav. 2003, 75:363-371.
8. De Boer P., Enrico P., Wright J., Wise L.D., Timmerman W., Moor E., Dijkstra D., Wikstrom H.V., Westerink B.H. Characterization of the effect of dopamine D3 receptor stimulation on locomotion and striatal dopamine levels. Brain Res. 1997, 758:83-91.
9. Di Ciano P., Underwood R.J., Hagan J.J., Everitt B.J. Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A. Neuropsychopharmacology 2003, 28:329-338.
10. Diaz J., Pilon C., Le Foll B., Gros C., Triller A., Schwartz J.C., Sokoloff P. Dopamine D3 receptors expressed by all mesencephalic dopamine neurons. J. Neurosci. 2000, 20:8677-8684.
11. Diaz S.L., Kemmling A.K., Balerio G.N. Baclofen reestablishes striatal and cortical dopamine concentrations during naloxone-precipitated withdrawal. Neurochem. Int. 2003, 42:293-298.
12. Gilbert J.G., Newman A.H., Gardner E.L., Ashby C.R., Heidbreder C.A., Pak A.C., Peng X.Q., Xi Z.X. Acute administration of SB-277011A, NGB 2904, or BP 897 inhibits cocaine cue-induced reinstatement of drug-seeking behavior in rats: role of dopamine D3 receptors. Synapse 2005, 57:17-28.
13. Heidbreder C.A, Andreoli M., Marcon C., Thanos P.K., Ashby C.R., Gardner E.L. Role of dopamine D3 receptors in the addictive properties of ethanol. Drugs Today (Barc) 2004, 40:355-365.
14. Heidbreder C.A., Gardner E.L., Xi Z.X., Thanos P.K., Mugnaini M., Hagan J.J., Ashby C.R. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res. Brain Res. Rev. 2005, 49:77-105.
15. Jezova D., Mlynarik M., Zelena D., Makara G.B. Behavioral sensitization to intermittent morphine in mice is accompanied by reduced adrenocorticotropine but not corticosterone responses. Brain Res. 2004, 1021:63-68.
16. Joseph J.D., Wang Y.M., Miles P.R., Budygin E.A., Picetti R., Gainetdinov R.R., Caron M.G., Wightman R.M. Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience 2002, 112:39-49.
17. Koob G.F., Kenneth Lloyd G., Mason B.J. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat. Rev. Drug Discov. 2009, 8:500-515.
18. Le Foll B., Goldberg S.R., Sokoloff P. The dopamine D3 receptor and drug dependence: effects on reward or beyond?. Neuropharmacology 2005, 49:525-541.
19. Leriche L., Schwartz J.C., Sokoloff P. The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. Neuropharmacology 2003, 45:174-181.
20. Leshner A.I. Addiction is a brain disease, and it matters. Science 1997, 278:45-47.
21. Levant B, Vansell N.R. In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology 1997, 17:67-71.
22. Narita M., Mizuo K., Mizoguchi H., Sakata M., Narita M., Tseng L.F., Suzuki T. Molecular evidence for the functional role of dopamine D3 receptor in the morphine-induced rewarding effect and hyperlocomotion. J. Neurosci. 2003, 23:1006-1012.
23. Pothos E., Rada P., Mark G.P., Hoebel B.G. Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res. 1991, 566:348-350.
24. Pritchard L.M, Logue A.D., Hayes S., Welge J.A., Xu M., Zhang J., Berger S.P., Richtand N.M. 7-OH-DPAT and PD 128907 selectively activate the D3 dopamine receptor in a novel environment. Neuropsychopharmacology 2003, 28:100-107.
25. Pritchard L.M., Newman A.H., McNamara R.K., Logue A.D., Taylor B., Welge J.A., Xu M., Zhang J., Richtand N.M. The dopamine D3 receptor antagonist NGB 2904 increases spontaneous and amphetamine-stimulated locomotion. Pharmacol. Biochem. Behav. 2007, 86:718-726.
26. Richtand N.M., Logue A.D., Welge J.A., Perdiue J., Tubbs L.J., Spitzer R.H., Sethuraman G., Geracioti T.D. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine. Brain Res. 2000, 867:239-242.
27. Richtand N.M., Woods S.C., Berger S.P., Strakowski S.M. D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci. Biobehav. Rev. 2001, 25:427-443.
28. Sautel F., Griffon N., Sokoloff P., Schwartz J.C., Launay C., Simon P., Costentin J., Schoenfelder A., Garrido F., Mann A. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther. 1995, 275:1239-1246.
29. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 1990, 347:146-151.
30. Suzuki T., Maeda J., Funada M., Misawa M. The D3-receptor agonist (+/-)-7-hydroxy-N,N-di-n-propyl-2-aminotetralin (7-OH-DPAT) attenuates morphine-induced hyperlocomotion in mice. Neurosci. Lett. 1995, 187:45-48.
31. Vanderschuren L.J., Kalivas P.W. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 2000, 151:99-120.
32. Vorel S.R., Ashby C.R., Paul M., Liu X., Hayes R., Hagan J.J., Middlemiss D.N., Stemp G., Gardner E.L. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci. 2002, 22:9595-9603.
33. Xu M., Koeltzow T.E., Santiago G.T., Moratalla R., Cooper D.C., Hu X.T., White N.M., Graybiel A.M., White F.J., Tonegawa S. Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 1997, 19:837-848.